Rapport Therapeutics, Inc. Common Stock (RAPP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rapport Therapeutics, Inc. Common Stock (RAPP) has a cash flow conversion efficiency ratio of -0.051x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.70 Million) by net assets ($484.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rapport Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Rapport Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Rapport Therapeutics, Inc. Common Stock for a breakdown of total debt and financial obligations.
Rapport Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rapport Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Befar Group Co Ltd
SHG:601678
|
0.015x |
|
JSL Construction & Development Co Ltd
TW:2540
|
-0.226x |
|
Lanzhou LS Heavy Equipment Co
SHG:603169
|
-0.002x |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
N/A |
|
Norwegian Air Shuttle ASA
OL:NAS
|
1.090x |
|
Grupo Aval Acciones y Valores S.A
F:6GAA
|
0.010x |
|
Allied Gold Corporation
NYSE:AAUC
|
0.432x |
|
Allied Blenders & Distillers Ltd
NSE:ABDL
|
N/A |
Annual Cash Flow Conversion Efficiency for Rapport Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Rapport Therapeutics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Rapport Therapeutics, Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $484.65 Million | $-87.47 Million | -0.180x | +14.97% |
| 2024-12-31 | $305.43 Million | $-64.83 Million | -0.212x | -120.02% |
| 2023-12-31 | $-25.63 Million | $-27.18 Million | 1.060x | +737.94% |
| 2022-12-31 | $19.50 Million | $-3.24 Million | -0.166x | -- |
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containin… Read more